Subject
Cancer Research,Cell Biology,Oncology
Reference115 articles.
1. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study;Abou-Alfa;Lancet Oncol.,2020
2. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study;Abou-Alfa;Lancet Oncol.,2020
3. Synthetic lethal vulnerabilities in KRAS-mutant cancers;Aguirre;Cold Spring Harb. Perspect. Med.,2018
4. Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity;Ahmed;J. Cell Biol.,2013
5. Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians;Allgauer;Transl. Lung Cancer Res.,2018
Cited by
164 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献